Top 10 Predicted First Time Solution Investments by U.S. Hospitals in 2018: Population Health Management and Laboratory - Molecular Diagnostics
We're predicting the technologies that U.S. hospitals will have largest increases in first time investment in 2018. We continue the countdown with the the 6th and 5th ranked technologies.
The predictions are based on installation data for 51 technologies from HIMSS Analytics LOGIC and LOGIC Predict, the predictive analytics engine within the platform. The base was the current footprint of 5,495 U.S. hospitals, 100% of the hospitals in the U.S.
At number 6 we see Population Health Management and predict Laboratory - Molecular Diagnostics at number 5.
#6 – Population Health Management
The solution with the 6th most first time solution investments by hospitals in 2018 is Population Health Management. Based on our predictions, we expect to see 154 U.S. hospitals buy this technology for the first time in 2018, resulting in a 2.8% increase in adoption.
In LOGIC, Population Health Management is defined as: “A solution designed to manage ‘the science and art of preventing disease, prolonging life, and promoting health through the organized efforts and informed choices of society, organizations, public and private communities, and individuals’”
Other notable information relevant to Population Health Management
The Center for Disease Control and Prevention (CDC) has a Division of Population Health that manages a diverse set of programs all focused on creating a healthier future for Americans. One such initiative was created out of the need for research to improve population health. As described by the CDC “In 1984, Congress authorized the US Department of Health and Human Services (HHS) to create a network of academic health centers to conduct applied public health research. CDC was funded in 1986 to provide leadership, technical assistance, and oversight for this network, which is called the Prevention Research Centers (PRC) Program.
CDC supports 26 centers connected with accredited schools of public health or schools of medicine with a preventive medicine residency program. Each center conducts at least one core research project with an underserved population that has high rates of disease and disability.”
Image credit: CDC.gov
#5 – Laboratory - Molecular Diagnostics
The solution with the 5th most first time solution investments by hospitals in 2018 is Laboratory – Molecular Diagnostics. Based on our predictions, we expect to see 158 U.S. hospitals buy this technology for the first time in 2018, resulting in a 2.9% increase in adoption.
In LOGIC, Laboratory – Molecular Diagnostics is defined as: “Borrowing from two new disciplines, genomics and proteomics, molecular diagnostics categorizes cancer using technology such as mass spectrometry and gene chips. Genomics is the study of all the genes in a cell or organism, while proteomics is the study of all the proteins. Molecular diagnostics determines how these genes and proteins are interacting in a cell. It focuses upon patterns--gene and protein activity patterns--in different types of cancerous or precancerous cells. Molecular diagnostics uncovers these sets of changes and captures this information as expression patterns. Also called "molecular signatures," these expression patterns are improving the clinicians' ability to diagnose cancer.”
Other notable information relevant to Laboratory - Molecular Diagnostics
From the U.S. National Library of Medicine National Institutes of Health: “Over the last decade, the field of molecular diagnostics has undergone tremendous transformation, catalyzed by the clinical implementation of next generation sequencing (NGS). As technical capabilities are enhanced and current limitations are addressed, NGS is increasingly capable of detecting most variant types and will therefore continue to consolidate and simplify diagnostic testing. It is likely that genome sequencing will eventually serve as a universal first line test for disorders with a suspected genetic origin. Academic Medical Centers (AMCs), which have been at the forefront of this paradigm shift are now presented with challenges to keep up with increasing technical, bioinformatic and interpretive complexity of NGS-based tests in a highly competitive market. Additional complexity may arise from altered regulatory oversight, also triggered by the unprecedented scope of NGS-based testing, which requires new approaches. However, these challenges are balanced by unique opportunities, particularly at the interface between clinical and research operations, where AMCs can capitalize on access to cutting edge research environments and establish collaborations to facilitate rapid diagnostic innovation.”
“…As AMC-associated diagnostic laboratories look to the future, several options enable a sustained contribution to the genetic and genomic testing market. These include: (1) Partnerships with commercial entities to compete in the rapidly evolving global genetic and genomic testing market, (2) Focus on local testing needs including support for higher volume tests and/or conversion of all rare disease testing to a common genomics platform and (3) Shifting focus to support for clinical research programs and other project-oriented endeavors.”